Alume Biosciences is developing bevonescein, a nerve illumination compound that enhances the visibility of critical nerves during surgery through fluorescence. This technology aims to reduce the incidence of nerve damage, which can lead to severe complications such as incontinence and facial paralysis in patients undergoing surgical procedures.

Amplo Biotechnology develops AAV-based gene therapies targeting the neuromuscular junction to treat genetic disorders such as Congenital Myasthenic Syndromes. Their lead candidates, AMP-101 and AMP-201, deliver the Dok-7 and Collagen Q proteins, respectively, to restore critical muscle function and address the underlying causes of these debilitating conditions.

Attralus is developing pan-amyloid removal (PAR) therapeutics that specifically target and eliminate toxic amyloid deposits in patients with systemic amyloidosis, addressing a critical gap in treatment options. This approach aims to reverse disease progression and improve patient outcomes, as current therapies do not remove amyloid from vital organs.

Creyon Bio engineers oligonucleotide-based medicines (OBMs) using machine learning models and custom data sets to create precise gene-centric therapies with minimal off-target effects. This approach enables the rapid development of safe and effective treatments for both rare and common diseases, significantly reducing costs and time to market.

CRISPR QC Analytics Platform provides real-time quantitative insights into ribonucleoprotein (RNP) formation, DNA target binding kinetics, and cleavage activity to enhance the efficiency of CRISPR gene editing workflows. By enabling researchers to pre-screen gRNA efficiency and optimize RNP assembly, the platform reduces the time and costs associated with troubleshooting and iterative screening in gene editing experiments.

The biopharmaceutical company specializes in life cycle management for botulinum toxin therapies, focusing on complications that arise from these treatments. By utilizing clinically validated molecules and repurposed drugs, the company provides targeted drug delivery solutions to enhance therapeutic outcomes.

Encoded develops a genetic‑medicine platform that uses precise cellular targeting and advanced gene‑regulation techniques to create one‑time gene therapies for neurological disorders. By identifying unique genetic signatures of disease‑relevant cells, the platform delivers therapeutic payloads with high specificity, improving potency and reducing off‑target effects for both monogenic and broader neurodegenerative conditions.

Equillium develops Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells in severe autoimmune and inflammatory disorders. The company also utilizes a proprietary multi-cytokine inhibitor platform to address the unmet medical needs associated with various inflammatory conditions.

This company offers mobile diagnostic labs that can be rapidly deployed to any healthcare setting. Their system performs a wide range of tests on-site, delivering results in under 30 minutes, while more complex tests are handled by a central lab, improving patient care and reducing healthcare resource utilization.

The startup develops in-feed technology that enables the oral delivery of antiparasitics and therapeutics for pets, enhancing treatment efficacy and compliance. This method provides a convenient alternative to traditional drug administration, ensuring safer and more effective pet care.

Minutia develops transplantable insulin‑producing cell clusters that embed nanoscale sensors for continuous in‑vivo monitoring of graft function. The integrated bioelectronic platform provides real‑time data on insulin secretion and cell viability, enabling clinicians to adjust therapy promptly and improve long‑term glycemic control for diabetes patients.

NeuraLace offers Axon Therapy®, a 100% non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed to treat chronic neuropathic pain without the need for needles or surgical interventions. This technology provides significant pain reduction, minimizing reliance on opioids and improving patient quality of life through targeted neuromodulation.

Nuvation Bio is a late clinical-stage biopharmaceutical company developing novel therapies targeting difficult-to-treat cancers that have shown resistance to conventional treatments. Their approach focuses on creating differentiated product candidates that aim to improve patient outcomes by enhancing efficacy and reducing side effects.

Persephone Biosciences utilizes artificial intelligence and synthetic biology to develop microbial-based immunotherapies that restore human microbiomes, addressing the health impacts of damaged ecosystems. Their approach aims to enhance therapeutic responses and improve patient outcomes in the fight against cancer.

Primmune Therapeutics is a biotechnology company focused on developing immune-modulating therapies to enhance the body's response to viral infections. Their approach targets specific pathways in the immune system to improve patient outcomes in infectious diseases.

PTM Therapeutics focuses on identifying disease-specific targets for therapeutic antibodies by leveraging Post Translational Modifications (PTMs). The company aims to develop new therapeutics for chronic diseases and cancer, addressing the need for more precise treatment options in these areas.

This company develops glucose-responsive insulin that automatically adjusts to blood sugar levels, eliminating the need for multiple daily injections. Their insulin aims to simplify diabetes management by combining basal and prandial insulin delivery into a single formulation, reducing the burden of frequent glucose monitoring.

The startup develops micronutrient therapeutics, including fatty acid supplements and food fortifiers, to enhance cellular function and maintain mitochondrial health. By targeting age-related cellular decline, their products aim to improve mood, reduce caloric intake, and boost fat metabolism.

Stuart Therapeutics develops PolyCol, a therapeutic platform utilizing synthetic amino acid sequences to specifically bind to and repair disease-damaged helical collagen in the extracellular matrix. This technology targets chronic ocular conditions such as Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration, which lead to inflammation, pain, and vision loss.

Tyra Biosciences develops precision molecules targeting acquired resistance pathways in oncology, utilizing a proprietary approach to drug design. The company aims to enhance treatment efficacy for cancer patients by addressing the limitations of existing therapies that fail due to resistance mechanisms.